RT Journal Article
T1 International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.
A1 Günther, Thomas
A1 Tulipano, Giovanni
A1 Dournaud, Pascal
A1 Bousquet, Corinne
A1 Csaba, Zsolt
A1 Kreienkamp, Hans-Jürgen
A1 Lupp, Amelie
A1 Korbonits, Márta
A1 Castaño, Justo P
A1 Wester, Hans-Jürgen
A1 Culler, Michael
A1 Melmed, Shlomo
A1 Schulz, Stefan
K1 Animals
K1 Gene expression regulation
K1 Humans
K1 Ligands
AB Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein-coupled receptors (GPCRs) called somatostatin receptor (SST)1-5. These five receptors share common structural features and signaling mechanisms but differ in their cellular and subcellular localization and mode of regulation. SST2 and SST5 receptors have evolved as primary targets for pharmacological treatment of pituitary adenomas and neuroendocrine tumors. In addition, SST2 is a prototypical GPCR for the development of peptide-based radiopharmaceuticals for diagnostic and therapeutic interventions. This review article summarizes findings published in the last 25 years on the physiology, pharmacology, and clinical applications related to SSTs. We also discuss potential future developments and propose a new nomenclature.
PB American Society for Pharmacology and Experimental Therapeutics
YR 2018
FD 2018
LK http://hdl.handle.net/10668/12965
UL http://hdl.handle.net/10668/12965
LA en
NO Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, et al. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev. 2018 Oct;70(4):763-835
DS RISalud
RD Apr 8, 2025